行情

CAPR

CAPR

Capricor
NASDAQ

实时行情|Nasdaq Last Sale

1.830
+0.050
+2.81%
盘后: 1.870 +0.04 +2.19% 19:33 01/17 EST
开盘
1.790
昨收
1.780
最高
1.875
最低
1.750
成交量
20.12万
成交额
--
52周最高
8.85
52周最低
1.000
市值
1,521.52万
市盈率(TTM)
-0.6453
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CAPR 新闻

  • 一个时代的终结? 二十世纪福克斯电影公司改名了
  • 中国新闻网.2小时前
  • 日经:日本拟在2030年实现6G
  • 新浪科技.2小时前
  • 关店1300家,真维斯真得卖不动了?
  • 新浪科技-自媒体综合.3小时前
  • 达沃斯新浪财经早餐会:国际视野下的ESG中国实践
  • 新浪财经.3小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

CAPR 简况

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
展开

Webull提供Capricor Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。